Guru Samuel Isaly purchased a 142,000-share stake in Puma Biotechnology Inc. (PBYI, Financial) in the first quarter.
Puma Biotechnology was incorporated in Delaware on April 27, 2007. It is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care. It is engaged in licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use.
The company licenses the rights to three drug candidates: PB272 (neratinib [oral]), which is being developed for the treatment of breast cancer patients, nonsmall cell lung cancer and patients with HER2 mutation-positive solid tumors; PB272 (neratinib [intravenous]), which is being developed for the treatment of cancer patients, and PB357, which it believes can serve as a backup compound to PB272 and is being evaluated for further development.
Puma Biotechnology has a market cap of $971.33 million, an enterprise value of $755.44 million and a P/B ratio of 4.70.
Puma Biotechnology is also traded in Germany.
According to GuruFocus, Puma Biotechnology has one good sign. The company's price is close to a three-year low, which may have influenced Isaly's decision to purchase a stake in the company in the first quarter.
Isaly may have decided to purchase a stake because the company is advancing in treatments for breast cancer.
It is possible that Isaly purchased shares because the price is close to a three-year low, and the company is developing new products that have the potential to cure various forms of cancer. The company also has a 6/10 financial strength rating, according to GuruFocus, with no debt, which is another good sign that may have influenced Isaly's decision to purchase shares of Puma Biotechnology.
Cheers to your investment success.
